Affordable Access

The use of strontium-90 in the treatment of carcinoma in situ of the conjunctiva.

Authors
Type
Published Article
Journal
American Journal of Ophthalmology
0002-9394
Publisher
Elsevier
Publication Date
Volume
87
Issue
1
Pages
84–86
Identifiers
PMID: 434057
Source
Medline
License
Unknown

Abstract

Four patients with carcinoma in situ were treated with strontium-90 beta ray application. The dose used was 4,500 rads after surgical removal or with small recurrent tumor and 7,000 rads for primary treatment. All patients were disease-free at follow-up periods of 48 to 320 months after treatment. One patient required superficial x-ray treatment for recurrent disease. No serious complications developed with the treatment and no progressive cataracts have occurred.

Statistics

Seen <100 times